Advanced Medical Solutions Group (CHIX:AMSL) Short Ratio


CHIX:AMSL Advanced Medical Solutions Group PLC CHIX:AMSL
93 GF Score
Price £2.81
GF Value £3.71
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Advanced Medical Solutions Group Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHIX:AMSL
93GF Score
Advanced Medical Solutions Group PLC CHIX:AMSL
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?

Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued. The current stock price of £2.81 is trading 24.3% below its estimated GF Value™ of £3.71. GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.

Key valuation signals for CHIX:AMSL:

  • Short Ratio:
  • GF Value™: £3.71 vs. price of £2.81 (24.3% below fair value)
  • GF Score™: 93/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Advanced Medical Solutions Group Business Description

Other Exchanges AMS:UKAQA:Germany
Address Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
93GF Score

Get the complete analysis for CHIX:AMSL

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£2.81
Price
£3.71
GF Value